Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis.

Satoshi Yoshiji Hiroto MinaminoDaisuke TanakaShunsuke YamaneNorio Harada Nobuya Inagaki

Published in: Diabetes, obesity & metabolism (2022)

The reduction in HbA1c, but not body weight, is associated with cardiovascular and renal outcomes. The magnitude of HbA1c reduction can be a surrogate for the cardiovascular and renal benefits of treatment with GLP-1 RAs.

Keyphrases

body weight
type diabetes
metabolic syndrome
skeletal muscle
combination therapy
glycemic control
replacement therapy